Corbus Pharmaceuticals Holdings, Inc.
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
About
CEO
Dr. Yuval Cohen Ph.D.
Employees
19
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
500 River Ridge Drive, Norwood, MA 02062, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 5, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| May 5, 2025 | — | — | — | — |
| Mar 10, 2025 | -1.02 | — | — | — |
| Nov 7, 2024 | -0.95 | -1.15 | -0.20 | 21.05% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 5 | — | 9 |
| Average estimate | — | -1.51 | — | -5.73 |
| Low estimate | — | -2.95 | — | -13.59 |
| High estimate | — | -0.77 | — | -3.36 |
| Last year EPS | — | -0.83 | — | -4.38 |
[stock_revenue_estimate]
Growth estimates
Current qtr
30.450%
Next qtr. (Mar 2025)
-82.170%
Current year
57.520%
Next year (Dec 2025)
-30.750%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | — | — | 881,705 | 3.94M | 36.14M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 31.17M | 16.14M | 36.45M | 98.27M | 89.60M |
| Selling general and admin | 13.91M | 18.70M | 20.43M | 28.48M | 23.64M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -45.08M | -34.84M | -55.99M | -122.81M | -77.10M |
| Non operating interest income | |||||
| Income | — | — | — | — | 1.23M |
| Expense | — | — | — | — | — |
| Other income expense | 3.40M | -5.38M | 12.18M | 12.57M | 4.42M |
| Pretax income | -44.60M | -42.35M | -45.64M | -111.27M | -71.45M |
| Tax provision | — | — | — | — | — |
| Net income | -44.60M | -42.35M | -45.64M | -111.27M | -71.45M |
| Basic EPS | -10.31 | -10.15 | -11.10 | -42.60 | -33.60 |
| Diluted EPS | -10.31 | -10.15 | -11.10 | -42.60 | -33.60 |
| Basic average shares | 4.33M | 4.17M | 4.10M | 2.60M | 2.13M |
| Diluted average shares | 4.33M | 4.17M | 4.10M | 2.60M | 2.13M |
| EBITDA | -44.45M | -28.74M | -54.63M | -120.41M | -75.72M |
| Net income from continuing op. | -44.60M | -42.35M | -45.64M | -111.27M | -71.45M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 28.27M | 66.31M | 107.73M | 102.29M | 49.14M |
| Current assets | |||||
| Cash | 4.03M | 3.81M | 6.75M | 1.24M | 884,115 |
| Cash equivalents | 9.69M | 13.20M | 18.26M | 84.19M | 30.86M |
| Cash and cash equivalents | 13.72M | 17.00M | 25.01M | 85.43M | 31.75M |
| Other short term investments | 7.18M | 42.19M | 72.64M | — | — |
| Accounts receivable | — | — | — | — | — |
| Other receivables | — | — | — | 2.58M | 2.68M |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 2.37M | 3.71M | 3.72M |
| Restricted cash | 192,475 | 192,475 | 192,475 | 350,000 | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 2.45M | 791,616 | 2.37M | 3.71M | 3.72M |
| Non current assets | |||||
| Properties | 3.06M | 3.88M | 4.61M | 5.25M | 5.82M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 1.20M | 1.38M | 1.43M | 2.25M | 2.34M |
| Construction in progress | — | — | — | — | — |
| Leases | 3.33M | 3.33M | 3.33M | 4.16M | 4.15M |
| Accumulated depreciation | -3.56M | -3.09M | -2.37M | -2.35M | -1.41M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 690,229 | 632,771 | 523,810 | 903,938 | 84,968 |
| Total liabilities | 35.18M | 33.32M | 38.62M | 57.02M | 42.98M |
| Current liabilities | |||||
| Accounts payable | 3.18M | 2.17M | 1.78M | 7.38M | 11.09M |
| Accrued expenses | 8.71M | 3.77M | 7.38M | 17.78M | 18.77M |
| Short term debt | 17.65M | 4.43M | 5.00M | 1.71M | 1.35M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 2.33M | 2.22M | 2.72M | 4.22M | 3.67M |
| Other current liabilities | 39,450 | 36,868 | 133,710 | 797,000 | — |
| Non current liabilities | |||||
| Long term debt | 3.24M | 20.66M | 21.59M | 25.12M | 8.10M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 44,411 | 22,205 | 22,205 | — | — |
| Shareholders equity | |||||
| Common stock | 442 | 417 | 416 | 9,885 | 6,467 |
| Retained earnings | -436.68M | -392.08M | -349.73M | -304.09M | -192.82M |
| Other shareholders equity | -1,556 | -126,092 | -62,445 | — | — |
| Total shareholders equity | -6.90M | 32.99M | 69.11M | 45.27M | 6.16M |
| Additional paid in capital | 429.78M | 425.20M | 418.90M | 349.36M | 198.98M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | -44.60M | -42.35M | -45.64M | -111.27M | -71.45M | -55.67M | -32.42M | -20.00M | -8.85M | -2.54M | -602,350 |
| Depreciation | 640,601 | 762,995 | 1.64M | 1.69M | 1.23M | 493,938 | 255,652 | 87,664 | 43,943 | 10,405 | — |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 3.47M | 5.72M | 9.48M | 12.46M | 11.98M | 7.61M | 5.69M | 3.16M | 1.15M | 193,120 | 6,141 |
| Other Non-Cash Items | 824,381 | 742,478 | 950,613 | 291,392 | — | 422,337 | 913,563 | 75,987 | — | -122,611 | 41,543 |
| Accounts Receivable | — | — | 1.62M | 1.06M | 2.32M | 12.50M | 1.00M | -1.00M | — | — | — |
| Accounts Payable | 1.03M | -256,835 | -5.96M | -3.47M | 4.37M | 3.90M | -885,797 | 1.89M | 972,194 | 170,239 | 131,849 |
| Other Assets & Liabilities | -494,784 | -521,051 | -772,000 | -893,885 | -5.53M | -4.79M | -1.98M | 88,577 | 1.85M | -13,728 | — |
| Operating Cash Flow | -39.13M | -35.90M | -38.68M | -100.13M | -57.09M | -35.53M | -27.42M | -15.69M | -4.83M | -2.30M | -422,817 |
| Investing Activities | |||||||||||
| Capital Expenditures | — | -5,349 | -30,272 | -484,491 | -2.74M | -2.30M | -707,429 | -353,032 | -114,037 | -64,448 | — |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -33.88M | -86.34M | -87.27M | — | — | — | — | — | — | — | — |
| Sale of Investments | 69.53M | 116.42M | 13.88M | — | — | — | — | — | — | — | — |
| Investing Cash Flow | 35.64M | 30.07M | -73.42M | -484,491 | -2.74M | -2.30M | -707,429 | -353,032 | -114,037 | -64,448 | — |
| Financing Activities | |||||||||||
| Long-Term Debt Issuance | — | 1.38M | — | 19.67M | 963,514 | 491,629 | 415,265 | 348,750 | 207,750 | 192,000 | 7,252 |
| Long-Term Debt Payments | -3.25M | -2.37M | -926,595 | -951,876 | -605,535 | -434,440 | -357,993 | -242,187 | -190,120 | -247,006 | — |
| Other Financing Charges | -190,902 | — | -1.82M | -6.04M | -2.57M | -690,181 | -2.94M | -63,830 | -509,215 | -1.87M | — |
| Financing Cash Flow | -3.25M | -1.40M | 59.90M | 153.92M | 38.82M | 11.48M | 76.07M | 16.85M | 10.85M | 8.33M | 134,504 |
| Other Cash Details | |||||||||||
| End Cash Position | 14.39M | 17.67M | 25.68M | 86.45M | 31.75M | 41.75M | 62.70M | 15.19M | 12.37M | 6.26M | 303,020 |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 2.61M | 1.97M | 1.74M | 629,146 | 29,448 | 10,437 | 12,377 | 5,586 | — | — | — |
| Free Cash Flow | -36.10M | -37.56M | -48.24M | -100.17M | -48.46M | -32.37M | -28.50M | -13.92M | -4.74M | -2.43M | -366,715 |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 371,620 | 4.21M | 3.05% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 329,220 | 3.73M | 2.70% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 291,904 | 3.31M | 2.40% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 169,055 | 1.92M | 1.39% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 105,154 | 1.19M | 0.86% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 67,807 | 768,253 | 0.56% |
| USAA Mutual Fund Tr-Science & Technology Fund | Oct 31, 2024 | 66,039 | 748,221 | 0.54% |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | Nov 30, 2024 | 57,707 | 653,820 | 0.47% |
| iShares Russell 2000 Growth ETF | Nov 30, 2024 | 55,701 | 631,092 | 0.46% |
| Vanguard Russell 2000 Index Fund | Nov 30, 2024 | 48,419 | 548,587 | 0.40% |
Article
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the Guggenheim SMID Cap Biotech Conference, to be held February 5-6, 2025 in New York, NY Dr. Cohen will participate in analyst led fireside discussion and will attend one-on-one investor meetings.
Jan 28, 2025
Article
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2025 in San Francisco, CA. Dr. Cohen will be presenting and attending investor meetings.
Jan 6, 2025
Article
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment
Dec 9, 2024
